

Bicant residues 161 to 236 of Figure 1A (SEQ ID NO:1).

17. (Amended) The antibody of claim 15 which [comprises] is a blocking antibody.

18. (Amended) The antibody of claim 15 which [comprises] is an antibody that, in addition to binding Apo-2 DcR polypeptide, binds to another Apo-2 ligand receptor.

19. (Amended) The antibody of claim 15 which [comprises] is a chimeric antibody.

20. (Amended) The antibody of claim 15 which [comprises] is a human antibody.

21. (Amended) The antibody of claim 15 which [comprises] is an IgG antibody.

B2 22. (Twice amended) The antibody of claim 16 having the [biological characteristics] the same in vitro or in vivo activities of the 4G3.9.9 monoclonal antibody produced by the hybridoma cell line deposited as ATCC accession number HB-12541.

23. (Twice amended) The antibody of claim 16 having the [biological characteristics] the same in vitro or in vivo activities of the 6D10.9.7 monoclonal antibody produced by the hybridoma cell line deposited as ATCC accession number HB-12542.

24. (Twice amended) The antibody of claim 16 having the [biological characteristics] the same in vitro or in vivo activities of the 1C5.24.1 monoclonal antibody produced by the hybridoma cell line deposited as ATCC accession number HB-12543.

B3 51. (Twice amended) An article of manufacture, comprising a container and a composition contained within said container, wherein the composition

173 includes one or more of the Apo-2 DcR antibodies of claim 15 as an active agent, and a carrier.

REMARKS

A. Sequences

In accordance with the Examiner's request and the rules of the MPEP (e.g., Section 2422), the specification, including the Brief Description of the Drawings, has been amended to recite the respective assigned Sequence Listing identifiers for the sequences referenced in the text and drawings.

Applicants do wish to bring to the Examiner's attention that the Sequence Listing as filed in the application did not include several of the sequences provided in Figure 2. Although Applicants did not receive a Notice to Comply to correct this aspect of the Sequence Listing, Applicants are filing herewith a substitute paper copy and computer-readable form of the Sequence Listing which properly includes the sequences referred to in Figure 2. These sequences now included in the substitute Sequence Listing are assigned SEQ ID NO:s 14-17, and are found in Figure 2 as originally filed in the application. This substitute Sequence Listing is believed to be in full compliance with the Sequence Listing rules provided in 37 CFR Section 1.821. A Certificate Regarding the Sequence Listing is also enclosed herewith.

B. Drawings

Applicants acknowledge the corrections needed for the formal drawings of the present application. Upon issuance of a notice of allowance for the present application, Applicants will file formal drawings with the corrected numbering of the figures, along with a Rule 312 amendment to amend the specification accordingly.

C. Specification

In the above amendment, the specification has been amended to recite the deposit information in the text of the specification. In Applicants' previously filed response, a copy of the ATCC confirmation sheet was provided.

D. Section 112 Rejections

Claims 15-24, 28 and 50-52 were rejected under Section 112, first